+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Duchenne Muscular Dystrophy (DMD) Treatment Market - Forecasts from 2019 to 2024

  • ID: 4835529
  • Report
  • July 2019
  • Region: Global
  • 101 pages
  • Knowledge Sourcing Intelligence LLP

FEATURED COMPANIES

  • FibroGen, Inc.
  • ITALFARMACO S.p.A.
  • NIPPON SHINYAKU CO., LTD.
  • Pfizer Inc.
  • PTC Therapeutics
  • ReveraGen BioPharma, Inc.
  • MORE
The Duchenne Muscular Dystrophy (DMD) treatment market is estimated to be valued at US$981.367 million in 2018 and is expected grow steadily during the forecast period. Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the mutation of the DMD gene, which is responsible for making a protein called dystrophin causing progressive muscle degeneration. At present, there is no cure for the disease, certain research strategies are being worked upon, however, the treatment is provided for the mitigation of disease symptoms. The growing incidence of rare diseases, rising R&D investments, growing adoption of genetic testing worldwide are some of the major drivers driving the growth of the Duchenne muscular dystrophy (DMD) treatment market during the forecast period. Furthermore, growing awareness regarding self-care and self-management resulting in early disease detection will help in the disease management in an efficient manner leading to sustainable market growth in the near future and beyond. The prevalence of Duchenne and Becker muscular dystrophy (DBMD) among Non-Hispanic blacks were lower than the prevalence among Hispanics and Non-Hispanic whites (Centers for Disease Control and Prevention, CDC). Thus, owing to high disease prevalence, North America and Europe are expected to hold a significant market share globally.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the Duchenne muscular dystrophy (DMD) treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics for providing a faster and efficient understanding of the Duchenne muscular dystrophy (DMD) treatment market.

Major industry players profiled as part of the report are Pfizer Inc., Sarepta Therapeutics, Inc., ReveraGen BioPharma, Inc., PTC Therapeutics, and NIPPON SHINYAKU CO., LTD. among others.

Segmentation

The duchenne muscular dystrophy (DMD) treatment market has been analyzed through following segments:

By Tests

Blood Test
Molecular Genetic Testing
Electromyography
Muscle Biopsy

By Treatment

Physical Therapy
Orthopedic Devices
Steroids
Others

By Geography

North America
USA
Canada
Mexico

South America
Brazil
Argentina
Others

Europe
Germany
France
United Kingdom
Spain
Others

Middle East and Africa
Saudi Arabia
Israel
Others

Asia Pacific
China
Japan
South Korea
India
Others
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • FibroGen, Inc.
  • ITALFARMACO S.p.A.
  • NIPPON SHINYAKU CO., LTD.
  • Pfizer Inc.
  • PTC Therapeutics
  • ReveraGen BioPharma, Inc.
  • MORE
1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS
4.1. Market Overview and Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Prevalence
4.5.1. By age group
4.5.2. By gender
4.5.3. By region
4.6. Product Pipeline
4.7. Innovations

5. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TESTS
5.1. Blood Test
5.2. Molecular Genetic Testing
5.3. Electromyography
5.4. Muscle Biopsy

6. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY TREATMENT
6.1. Physical Therapy
6.2. Orthopedic Devices
6.3. Steroids
6.4. Others

7. DUCHENNE MUSCULAR DYSTROPHY (DMD) TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others

8. COMPETITIVE INTELLIGENCE
8.1. Competitive Benchmarking and Analysis
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES
9.1. Pfizer Inc.
9.2. Sarepta Therapeutics, Inc.
9.3. ReveraGen BioPharma, Inc.
9.4. PTC Therapeutics
9.5. NIPPON SHINYAKU CO.,LTD.
9.6. ITALFARMACO S.p.A.
9.7. FibroGen, Inc.
9.8. DAIICHI SANKYO COMPANY, LIMITED.
9.9. Solid Biosciences Inc.
Note: Product cover images may vary from those shown
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • ReveraGen BioPharma, Inc.
  • PTC Therapeutics
  • NIPPON SHINYAKU CO., LTD.
  • ITALFARMACO S.p.A.
  • FibroGen, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Solid Biosciences Inc.
Note: Product cover images may vary from those shown
Adroll
adroll